Pfizer Wins $10 Billion Battle for Metsera in Obesity Drug Market
TL;DR Summary
Pfizer agreed to acquire Metsera for $10 billion after a bidding war with Novo Nordisk, with Pfizer securing US regulatory approval and offering a higher bid, aiming to strengthen its position in the growing obesity drug market.
- Pfizer to Buy Metsera for $10 Billion, Capping Bidding War Bloomberg.com
- Metsera accepts Pfizer's $10 billion bid in ongoing M&A battle Reuters
- Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal The New York Times
- Novo Nordisk CEO Challenges Pfizer to Raise its Bid for Metsera Bloomberg.com
- Pfizer matches Novo bid for obesity biotech Metsera as takeover battle rages Financial Times
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
4 min
vs 5 min read
Condensed
96%
855 → 37 words
Want the full story? Read the original article
Read on Bloomberg.com